SCI PHARMTECH, INC.
旭富製藥科技

簡報

ISO 14001
BUREAU VERITAS
Certification

ISO 9001
BUREAU VERITAS
Certification

公司概況Profile

- 員工數Employee：214
- 設立日期：中華民國七十六年九月十八日
  Date of establishment: Sep. 18, 1987
- 資本額Capital：新台幣953佰萬元(NTD 953mn)
- 營業項目Business：
  原料藥API（83.22%）
  中間體Intermediate（16.50%）
  其他 Other chemicals（0.28%）

營運概況-IS

Unit: K NTD

	2022Y
營收Sales	899,738
營業成本COGS	(608,559)
毛利Gross Profit	291,179
毛利率 GP Ratio	32.4%
營業費用Operating Expenses	(172,209)
營業利益Operating Income	118,970
營業外損益Non-Operating In/Ex	268,850
稅前淨利 Net Profit before Tax	387,820
所得稅Income Tax	(79,040)
本期淨利Net Profit after Tax	308,780

產品組合-Products

Sales Product	%	Jan~Feb, 2023 (K NT$)
Pent-2 / PEB.Na	49.4%	98,074
BZA	16.2%	32,184
VA series	14.4%	28,626
PGA	8.6%	17,077
Dulo.Hcl	6.3%	12,544
PF.Hcl	1.7%	3,423

VA Series:

Valproic Acid, Divalproex Sodium, Sodium Valproate

- 適應症 Application：
  癲癇(seizure)、躁鬱症(bipolar disorder)、
  偏頭痛(migraine headaches)



Pyrogallolaldehyde (PGA)

Benserazide

治療帕金森氏症之中間體

Intermediate for Parkinson's Disease



Pent-2 / Pentobarbital Sodium

鎮定安眠用中間體及原料藥

Intermediate and API for calmative



Brinzolamide

- 青光眼原料藥

API for Glaucoma medication



Hydroxychloroquine sulfate

- 適應症 Application:
  類風濕性關節炎(rheumatoid arthritis) 、瘧疾 (malaria)、慢性多形性日光疹、慢性圓板狀紅斑症 (discoid and systemic lupus erythematosus)



S-MMAA / Duloxetine HCl

- 適應症 Application:
  重鬱症(major depressive disorder)、廣泛性焦慮症(generalized anxiety disorder) 、糖尿病週邊神經痛(diabetic neuropathy) 、纖維肌痛（Fibromyalgia)、慢性腰痛(日本地區) lower back pain (only in Japan)



觀音廠平面圖(Layout of Guanyin Plant)



觀音廠進度(Building progress)

- 觀音廠資本支出計20億，目前已支付，預計2024年第3季試量產，前期提供約蘆竹廠25%產能
- 蘆竹廠目前產能約回復40%，5月至55%，6月至70%，9月重建完成
- 資本支出採銀行借款及保險金因應，2022年底銀行借款544佰萬，負債比率28%
- 目前鄰廠損失已98%之金額談定及賠付
- 目前正在進行第三次保險預付款項申請

- The capital expenditure of Guanyin factory is 2 billion, 450 million of which has been paid. It is expected to be operational in the third quarter of 2024, and provide about 25% of the production capacity of Luzhu factory in the 1st stage.

- The current production capacity of the Luzhu Factory has recovered by about 40%, expected to reach 55% in May and 70% in June, and the reconstruction will be completed in September.

- Capital expenditure relays on bank loans and insurance claims. As of Dec. 31, 2022, bank loans were at 544 million with debt ratio of 28%.

- At present, 98% of the compensation to the adjacent factory has been settled and paid.

- We are applying for the third piece of insurance claim.

(I)	API	DMF (USA)	CEP (EDQM)	MF (Japan)	DMF (Canada)	CGMP certified (TFDA)	China DMF
1	Adenine	2022					
2	Articaine Hydrochloride	2014	2014			2013	2021
3	Allopurinol	2011	2003			2004	
4	Atomoxetine Hydrochloride	2018	2018			2016	
5	Bisoprolol Fumarate					2006	
6	Brinzolamide	2015		2017		2022 (GDP)	
7	Clindamycin Palmitate HCl	2011					
8	Divalproex Sodium	2005			2010	2022 (GDP)	2010
9	Duloxetine Hydrochloride	2011	2014	2017	2016	2022 (GDP)	2013
10	Hydroxychloroquine Sulfate	2014	2019		2014	2014	2020
11	Loxoprofen Sodium Hydrate			2011		2012	
12	Methylphenidate HCl		2014			2022 (GDP)	
13	Pentobarbital Sodium		2011			2022 (GDP)	
14	Probucol	2004		2017	2015	2022 (GDP)	
15	Propafenone Hydrochloride	2010	2012	2012	2012	2022 (GDP)	2018
16	Sodium Valproate	2019	2006	2017		2022 (GDP)	2014
17	Thiopental					2020	
18	Valproic Acid	2003	2004	2008	2008	2022	2019
19	Cannabidiol (CBD)	2020				2020	
(II)	API intermediate	DMF (USA)	CEP (EDQM)	MF (Japan)	DMF (Canada)	CGMP certified (TFDA)	
1	Menthadienol (PMDOL)	2019					
2	Olivetol	2019					
3	Ethyl Olivetolate	2019					

簡 報 完 畢

敬 請 指 教